Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 16 ... BARACLUDE is not recommended for HIV/HBV co-infected patients who are not also receiving highly active antiretroviral therapy (HAART). Before initiating BARACLUDE therapy, HIV antibody testing should be offered to ...
2009 NOV 23 ... virus (HIV) infection is well documented, especially with regard to adherence to highly active antiretroviral therapy (HAART). We used the data from a 5-year longitudinal study of the MANIF 2000 cohort of ...
2009 NOV 9 ... non-AIDS-defining malignancies (non-ADMs) is reported as unchanged or increasing in the highly active antiretroviral therapy era. Whether incidence of non-ADM is significantly higher in HIV-infected than in ...
2009 NOV 16 ... in women who are infected with human immunodeficiency virus (HIV) and who receive highly active antiretroviral therapy compared with the general population DESIGN: In this retrospective cohort study, we ...
2009 NOV 9 ... Syndromes, "Alcohol use is frequently implicated as a factor in nonadherence to highly active antiretroviral therapy (HAART). There have not been efforts to systematically evaluate findings across ...
2009 NOV 9 ... been a major global health problem for almost three decades. With the introduction of highly active antiretroviral therapy in 1996, and the advent of effective prophylaxis and management of opportunistic ...
2009 NOV 23 ... of a failure to achieve high CD4 cell counts while receiving virally suppressive highly active antiretroviral therapy (HAART) are uncertain. We analysed data from HIV-infected men participating in the ...
2009 NOV 9 ... with hepatitis B virus (HBV) or hepatitis C virus (HCV). He had been treated with highly active antiretroviral therapy (HAART) since 1990," wrote R.V. Dinavahi and colleagues. The researchers ...
2009 NOV 9 ... prevalence, viral load and pre-cancerous lesions of the cervix in women initiating highly active antiretroviral therapy in South Africa: a cross-sectional study. BMC Cancer, 2009;9():275). For ...
2009 NOV 9 ... maintenance have no proven benefit and are not recommended. The more widespread use of highly active antiretroviral therapy in the HIV patient with BL has allowed the use of similar aggressive therapies that are ...
2009 NOV 9 ... to establish a latent infection causes life-long virus persistence, even after long-term highly active antiretroviral therapy (HAART). The role that latency is playing in preventing clearance of the virus infection ...
2009 NOV 2 ... jirovecii-associated organizing pneumonia (PJP) in an HIV-infected individual on highly active antiretroviral therapy (HAART) with a CD4(+) T-cell count of 835 x 10(3) cells/mL and a low viral load. PJP was ...
2009 NOV 9 ... Health Centre (RI-MUHC). IL-2 is currently used as a complement to highly active antiretroviral therapy (known as HAART), which is administered to patients with HIV-AIDS. Since HAART controls ...
2009 NOV 9 ... According to recent research from the United States, "As highly active antiretroviral therapy (ART) is introduced into areas of the world in which hepatitis B virus (HBV) infection ...
2009 NOV 2 ... type 1 (HIV-1)-infected individuals who achieve viral loads of <50 copies/ml during highly active antiretroviral therapy (HAART), low levels of plasma virus remain detectable for years by ultrasensitive ...
2009 NOV 1 ... "The effects of highly active antiretroviral therapy (HAART) on the prevalence of endodontic diseases in HIV-infected individuals have not ...
2009 NOV 16 ... "Our current knowledge on the antiviral efficacy, dosing, and toxicity of available highly active antiretroviral therapy regimens is mostly derived from plasma or blood kinetics of anti-human immunodeficiency ...
2009 NOV 9 ... risk [RR] 0.53 per 100 cell increase, 95% confidence interval [CI] 0.34, 1.02) and highly active antiretroviral therapy (HAART) use during TB therapy (RR 0.37, 95% CI 0.13, 1.02) were independently associated ...
2009 NOV 9 ... concentration (>= 4.0 mg/L) while using efavirenz 600 mg once daily as part of their highly active antiretroviral therapy regimen were selected from the AIDS Therapy Evaluation in The Netherlands cohort ...
2009 NOV 1 ... New research, 'The safety of highly active antiretroviral therapy for the HIV-positive pregnant mother and her baby: is 'the more the merrier',' is the ...
